StockData
Vaxart, Inc. logo

Vaxart, Inc. (VXRT) stock

VXRTOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.48+0.02 (+5.04%)

Close on Oct 19, 2026Market cap $115.61MP/E 4.0Yield –

Vaxart enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Vaxart's enterprise value was $51.47M on Oct 19, 2026, against $50.29M a year earlier. Over the last 5 years it ranged from $6.29M to $809.68M, with a median of $81.57M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Oct 19, 2026$51.47M+1.9%
2025Dec 31, 2025$50.51M-45.0%
2024Dec 31, 2024$91.91M+173.0%
2023Dec 29, 2023$33.66M+299.2%
2022Dec 30, 2022$8.43M-98.6%
2021Dec 31, 2021$597.93M+1.1%
2020Dec 31, 2020$591.63M–
2019Dec 31, 2019-$3.38M–
2018Dec 31, 2018-$2.18M-101.3%
2017Dec 29, 2017$173.58M-61.8%
2016Dec 30, 2016$454.11M-40.9%
2015Dec 31, 2015$768.01M-4.7%
2014Dec 31, 2014$806.09M-35.3%
2013Dec 31, 2013$1.25B+31.2%
2012Dec 31, 2012$949.80M-84.7%
2011Dec 30, 2011$6.22B-67.7%
2010Dec 31, 2010$19.29B–

More Vaxart figures

See a number that looks wrong?